Lista de obras - P Nash - Dominio Público Uruguay

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

scientific article published on 27 February 2019

2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews

artículo científico publicado en 2020

A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis

artículo científico publicado en 2015

APLAR rheumatoid arthritis treatment recommendations.

artículo científico publicado en 2015

Advances in rheumatoid arthritis

artículo científico publicado en 2017

Alefacept plus methotrexate for psoriatic arthritis

artículo científico publicado en 2006

An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3

artículo científico publicado en 2014

Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmona

artículo científico

Assessment of patients with psoriatic arthritis: a review of currently available measures

artículo científico publicado en 2004

Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.

artículo científico publicado en 2010

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison

scientific article published on 30 October 2018

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

artículo científico publicado en 2018

Consensus on a core set of domains for psoriatic arthritis

artículo científico publicado en 2007

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

artículo científico publicado en 2018

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease ⬇️

scientific article published on 29 October 2018

Drug use and toxicity in psoriatic disease: focus on methotrexate

artículo científico publicado en 2008

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update ⬇️

artículo científico publicado en 2017

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

artículo científico publicado en 2018

Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group

scientific article published on December 2009

Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health

artículo científico publicado en 2010

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial

artículo científico publicado en 2015

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

artículo científico publicado en 2004

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

artículo científico publicado en 2018

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

artículo científico publicado en 2015

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update ⬇️

artículo científico

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

artículo científico publicado en 2012

GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. ⬇️

artículo científico publicado en 2017

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

article

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

scientific article published on 01 August 2009

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function fin

artículo científico publicado en 2013

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

artículo científico publicado en 2016

How Can We Improve the Use of Established Therapies in PsA?

artículo científico publicado en 2020

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.

artículo científico publicado en 2017

Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study ⬇️

artículo científico publicado el 1 de mayo de 2013

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

artículo científico publicado en 2020

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis

artículo científico publicado en 2015

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor in

scientific article published on 07 September 2018

Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

artículo científico publicado en 2006

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment

artículo científico publicado en 2014

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

artículo científico publicado en 2017

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

artículo científico publicado en 2020

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

artículo científico publicado en 2018

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

artículo científico publicado en 2013

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis

scientific article published on 26 February 2019

Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

artículo científico publicado en 2009

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

artículo científico publicado en 2020

N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study

artículo científico publicado en 2012

Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis

artículo científico publicado en 2006

Outcome measures in psoriatic arthritis

artículo científico publicado en 2007

Outcome measures in psoriatic arthritis

artículo científico publicado en 2005

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.

artículo científico publicado en 2017

Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.

artículo científico publicado en 2013

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

artículo científico publicado en 2020

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research

artículo científico publicado en 2020

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

artículo científico publicado en 2011

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

artículo científico publicado en 2003

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.

artículo científico publicado en 2005

Psoriatic arthritis: novel targets add to a therapeutic renaissance

artículo científico publicado en 2018

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

artículo científico publicado en 2009

Real-world Evidence Needs Careful Interpretation

artículo científico publicado en 2021

Registries in systemic sclerosis: a worldwide experience ⬇️

artículo científico publicado el 1 de enero de 2011

Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study.

artículo científico publicado en 2010

Remission in psoriatic arthritis-where are we now? ⬇️

artículo científico publicado en 2017

Reply

artículo científico publicado en 2016

Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?

artículo científico publicado en 2014

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

artículo científico publicado en 2018

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

scientific article published on 12 February 2019

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

artículo científico publicado en 2018

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis

artículo científico publicado en 2018

Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial

artículo científico publicado en 2004

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

artículo científico publicado en 2014

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

artículo científico publicado en 2011

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed

artículo científico publicado en 2011

The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

artículo científico publicado en 2009

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

artículo científico publicado en 2012

The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.

artículo científico publicado en 2013

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study

scientific article published on 24 April 2019

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

scientific article published on 11 June 2018

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force ⬇️

artículo científico

Treatment goals for moderate to severe psoriasis: an Australian consensus.

artículo científico publicado en 2013

Treatment outcomes in patients with seropositive versus seronegative rheumatoid arthritis in Phase III randomised clinical trials of tofacitinib

artículo científico publicado en 2019

Treatment patterns among patients with rheumatic disease (rheumatoid arthritis (RA), ankylosing spondylitis (AS), psoriatic arthritis (PsA) and undifferentiated arthritis (UnA)) treated with subcutaneous TNF inhibitors.

artículo científico publicado en 2018

Treatment recommendations for psoriatic arthritis.

scientific article published on 24 October 2008

Updated guidelines for the management of axial disease in psoriatic arthritis

artículo científico publicado en 2014

Validation of the 6 min walk test according to the OMERACT filter: a systematic literature review by the EPOSS-OMERACT group

artículo científico publicado en 2010

Vertebral Fracture Risk With Long-term Corticosteroid Therapy

article

Lista de obras de P Nash

2018 update of the APLAR recommendations for treatment of rheumatoid arthritis

2019 update: EULAR RA management recommendations, efficacy and safety systematic literature reviews

A comparison of the predictive accuracy of three screening models for pulmonary arterial hypertension in systemic sclerosis

APLAR rheumatoid arthritis treatment recommendations.

Advances in rheumatoid arthritis

Alefacept plus methotrexate for psoriatic arthritis

An Immunochip-based interrogation of scleroderma susceptibility variants identifies a novel association at DNASE1L3

Analysis of the validation status of quality of life and functional disability measures in pulmonary arterial hypertension related to systemic sclerosis: results of a systematic literature analysis by the Expert Panel on Outcomes Measures in Pulmona

Assessment of patients with psoriatic arthritis: a review of currently available measures

Characteristics of joint involvement and relationships with systemic inflammation in systemic sclerosis: results from the EULAR Scleroderma Trial and Research Group (EUSTAR) database.

Comparative effectiveness of secukinumab and adalimumab in ankylosing spondylitis as assessed by matching-adjusted indirect comparison

Comparative effectiveness of secukinumab and etanercept in biologic-naïve patients with psoriatic arthritis assessed by matching-adjusted indirect comparison

Consensus on a core set of domains for psoriatic arthritis

Correction to: Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Disease-specific composite measures for psoriatic arthritis are highly responsive to a Janus kinase inhibitor treatment that targets multiple domains of disease ⬇️

Drug use and toxicity in psoriatic disease: focus on methotrexate

EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2016 update ⬇️

Early and sustained efficacy with apremilast monotherapy in biological-naïve patients with psoriatic arthritis: a phase IIIB, randomised controlled trial (ACTIVE).

Echocardiography as an outcome measure in scleroderma-related pulmonary arterial hypertension: a systematic literature analysis by the EPOSS group

Effect of psoriatic arthritis according to the affected categories of the international classification of functioning, disability and health

Efficacy and Safety of Subcutaneous Golimumab in Methotrexate-Naive Patients With Rheumatoid Arthritis: Five-Year Results of a Randomized Clinical Trial

Efficacy and safety of adalimumab as monotherapy in patients with rheumatoid arthritis for whom previous disease modifying antirheumatic drug treatment has failed

Efficacy and safety of secukinumab administration by autoinjector in patients with psoriatic arthritis: results from a randomized, placebo-controlled trial (FUTURE 3).

Efficacy and safety of tofacitinib following inadequate response to conventional synthetic or biological disease-modifying antirheumatic drugs

Evidence for treating rheumatoid arthritis to target: results of a systematic literature search update ⬇️

Extent of disease on high-resolution computed tomography lung is a predictor of decline and mortality in systemic sclerosis-related interstitial lung disease.

GRAPPA-OMERACT consensus-based recommendations and research agenda for use of composite measures and treatment targets in PsA. ⬇️

Golimumab in patients with active rheumatoid arthritis despite treatment with methotrexate: A randomized, double-blind, placebo-controlled, dose-ranging study

Golimumab, a human anti-tumor necrosis factor α monoclonal antibody, injected subcutaneously every four weeks in methotrexate-naive patients with active rheumatoid arthritis: Twenty-four-week results of a phase III, multicenter, randomized, double-b

Golimumab, a human anti–tumor necrosis factor monoclonal antibody, injected subcutaneously every 4 weeks in patients with active rheumatoid arthritis who had never taken methotrexate: 1-year and 2-year clinical, radiologic, and physical function fin

Group for Research and Assessment of Psoriasis and Psoriatic Arthritis 2015 Treatment Recommendations for Psoriatic Arthritis

How Can We Improve the Use of Established Therapies in PsA?

Identification of biomarkers of response to abatacept in patients with SLE using deconvolution of whole blood transcriptomic data from a phase IIb clinical trial.

Immunogenicity, Safety, and Efficacy of Abatacept Administered Subcutaneously With or Without Background Methotrexate in Patients With Rheumatoid Arthritis: Results From a Phase III, International, Multicenter, Parallel‐Arm, Open‐Label Study ⬇️

Impact of guselkumab, an interleukin-23 p19 subunit inhibitor, on enthesitis and dactylitis in patients with moderate to severe psoriatic arthritis: results from a randomised, placebo-controlled, phase II study

Interpretation of an Extended Autoantibody Profile in a Well-Characterized Australian Systemic Sclerosis (Scleroderma) Cohort Using Principal Components Analysis

Ixekizumab is efficacious when used alone or when added to conventional synthetic disease-modifying antirheumatic drugs (cDMARDs) in patients with active psoriatic arthritis and previous inadequate response or intolerance to tumour necrosis factor in

Leflunomide improves psoriasis in patients with psoriatic arthritis: an in-depth analysis of data from the TOPAS study.

Long-term safety of subcutaneous abatacept in rheumatoid arthritis: integrated analysis of clinical trial data representing more than four years of treatment

Long-term safety of tofacitinib for the treatment of rheumatoid arthritis up to 8.5 years: integrated analysis of data from the global clinical trials.

Long-term safety of tofacitinib up to 9.5 years: a comprehensive integrated analysis of the rheumatoid arthritis clinical development programme

Longterm Safety and Efficacy of Subcutaneous Abatacept in Patients with Rheumatoid Arthritis: 5-year Results from a Phase IIIb Trial.

Maintenance, reduction, or withdrawal of etanercept after treatment with etanercept and methotrexate in patients with moderate rheumatoid arthritis (PRESERVE): a randomised controlled trial.

Matching-adjusted indirect comparison: secukinumab versus infliximab in biologic-naive patients with psoriatic arthritis

Measures of response in clinical trials of systemic sclerosis: the Combined Response Index for Systemic Sclerosis (CRISS) and Outcome Measures in Pulmonary Arterial Hypertension related to Systemic Sclerosis (EPOSS).

Multicentre, randomised, open-label, parallel-group study evaluating the efficacy and safety of ixekizumab versus adalimumab in patients with psoriatic arthritis naïve to biological disease-modifying antirheumatic drug: final results by week 52

N-terminal pro-brain natriuretic peptide in a novel screening algorithm for pulmonary arterial hypertension in systemic sclerosis: a case-control study

Need for improved outcome measures in pulmonary arterial hypertension related to systemic sclerosis

Outcome measures in psoriatic arthritis

Outcome measures in psoriatic arthritis

Patient and Healthcare Professionals Preference for Brenzys vs. Enbrel Autoinjector for Rheumatoid Arthritis: A Randomized Crossover Simulated-Use Study.

Perceptions of methotrexate use in rheumatoid arthritis by rheumatologists and their patients: an Australian survey study.

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a consensus statement

Points to consider for the treatment of immune-mediated inflammatory diseases with Janus kinase inhibitors: a systematic literature research

Prevalence, correlates and clinical usefulness of antibodies to RNA polymerase III in systemic sclerosis: a cross-sectional analysis of data from an Australian cohort.

Prevention and treatment of glucocorticoid-induced osteoporosis: a comparison of calcitriol, vitamin D plus calcium, and alendronate plus calcium.

Psoriatic arthritis therapy: NSAIDs and traditional DMARDs.

Psoriatic arthritis: novel targets add to a therapeutic renaissance

Pulmonary arterial hypertension: the most devastating vascular complication of systemic sclerosis.

Real-world Evidence Needs Careful Interpretation

Registries in systemic sclerosis: a worldwide experience ⬇️

Relationship between rheumatoid arthritis disease severity, health-related utility, and resource use in Australian patients: A cross-sectional, multicenter study.

Remission in psoriatic arthritis-where are we now? ⬇️

Reply

Rheumatoid arthritis in the Middle East and Africa: are we any closer to optimising its management?

Safety and efficacy of ixekizumab in patients with PsA and previous inadequate response to TNF inhibitors: week 52 results from SPIRIT-P2

Safety of Ixekizumab in Patients With Psoriatic Arthritis: Results From a Pooled Analysis of Three Clinical Trials

Secukinumab Versus Adalimumab for Psoriatic Arthritis: Comparative Effectiveness up to 48 Weeks Using a Matching-Adjusted Indirect Comparison.

Secukinumab for psoriatic arthritis: comparative effectiveness versus licensed biologics/apremilast: a network meta-analysis

Short course prednisolone for adhesive capsulitis (frozen shoulder or stiff painful shoulder): a randomised, double blind, placebo controlled trial

Subcutaneous abatacept for the treatment of rheumatoid arthritis: longterm data from the ACQUIRE trial.

Subcutaneous abatacept versus intravenous abatacept: a phase IIIb noninferiority study in patients with an inadequate response to methotrexate.

Systemic sclerosis-associated pulmonary hypertension: why disease-specific composite endpoints are needed

The challenge of early systemic sclerosis for the EULAR Scleroderma Trial and Research group (EUSTAR) community. It is time to cut the Gordian knot and develop a prevention or rescue strategy

The development of candidate composite disease activity and responder indices for psoriatic arthritis (GRACE project)

The inclusion of N-terminal pro-brain natriuretic peptide in a sensitive screening strategy for systemic sclerosis-related pulmonary arterial hypertension: a cohort study.

Tofacitinib in Combination With Methotrexate in Patients With Rheumatoid Arthritis: Clinical Efficacy, Radiographic, and Safety Outcomes From a Twenty-Four-Month, Phase III Study

Tofacitinib, an Oral Janus Kinase Inhibitor: Pooled Efficacy and Safety Analyses in an Australian Rheumatoid Arthritis Population

Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force ⬇️